Search Patents
-
Patent number: 5177190Abstract: A method is disclosed for isolating and purifying C5a receptor from human polymorphonuclear leukocytes. C5a is a complement-derived protein which is important as a mediator of inflammatory responses. C5a receptor may be used to screen create and quantify C5a antagonists useful as anti-inflammatory agents and immunoregulants and to generate monoclonal and polyclonal anti-C5a receptor antibodies useful as anti-inflammatory agents and immunoregulants.Type: GrantFiled: January 22, 1992Date of Patent: January 5, 1993Assignee: Merck & Co., Inc.Inventors: Thomas E. Rollins, Martin S. Springer
-
Patent number: 5109114Abstract: A purified protein, factor J, which has inhibitory properties which prevent the formation or the dissociation of C1 complex and a method of purification for said protein. The method including the following sequential chromatography steps: anion exchange, QAE-Sephadex, heparin-Sepharose affinity, Mono-Q and hydroxylapatite.Type: GrantFiled: September 12, 1989Date of Patent: April 28, 1992Assignee: Beth Israel HospitalInventor: Anne Nicholson-Weller
-
Patent number: 5453490Abstract: A method for the production of commercial quantities of highly purified interleukin-1 inhibitor (IL-1i) from a recombinant host is disclosed. A preferred recombinant E. coli host for use in this method is also disclosed.Type: GrantFiled: August 30, 1994Date of Patent: September 26, 1995Assignee: Synergen, Inc.Inventors: Robert Hageman, Stephen P. Eisenberg, David Dripps, Ronald Evans, Henryk Cudny, Robert C. Thompson
-
Patent number: 5225537Abstract: Methods are disclosed for producing hybrid phospholipid-binding proteins from eukaryotic cells. DNA constructs comprising a transcriptional promoter, at least one signal sequence and a hybrid phospholipid-binding protein coding sequence comprising at least one lipocortin lipid-binding domain joined to a gla-domainless, vitamin K-dependent protein and a transcriptional terminator are also disclosed.Type: GrantFiled: December 29, 1989Date of Patent: July 6, 1993Assignee: ZymoGenetics, Inc.Inventor: Donald C. Foster
-
Patent number: 5196516Abstract: The present invention is concerned with a pseudorabies virus (PRV) vaccine comprising a polypeptide of the PRV glycoprotein gII or a fragment thereof which was shown to be the site of interaction of PRV neutralizing antibodies. Vector vaccines capable to express a polynucleotide fragment coding for such a polypeptide also form part of the present invention.Type: GrantFiled: July 21, 1989Date of Patent: March 23, 1993Assignee: Akzo N.V.Inventors: Christa S. Schreurs, Thomas C. Mettenleiter, Artur J. Simon, Noemi Lukacs, Hanns J. Rziha
-
Patent number: 5273744Abstract: This invention relates to the development of a vaccine against Theileria parva, which is a protozoan parasite infecting cattle in Africa. The invention specifically relates to the use of the 67 kDa glycoprotein from the surface of the T. parva sporozoite as an immunogen for inducing immunoprotection against T. parva in bovine species. This 67 kDa antigen is produced using recombinant genetics. Plasmids containing nucleic acid segments encoding the antigen, host cells containing the nucleic acid segments and recombinant methods for producing the antigen are part of this invention.Type: GrantFiled: February 11, 1992Date of Patent: December 28, 1993Assignee: International Laboratory for Research on Animal DiseasesInventors: Anthony J. Musoke, Vish Nene, Keith Iams, Vinand M. Nantulya
-
Patent number: 6239101Abstract: Small, buffer soluble polypeptides having amino acid structures corresponding to residues 234-486, 310-486, and 407-486, of thrombomodulin and functionally equivalent analogs thereof inhibiting the clotting activity of thrombin and increasing protein C activation. The polypeptides can be coated onto the surface of articles adapted for contacting mammalian blood to render the surface non-thrombogenic. In pharmaceutical compositions, the polypeptides act as a natural anticoagulant.Type: GrantFiled: January 31, 1991Date of Patent: May 29, 2001Assignee: Oklahoma Medical Research FoundationInventors: Charles T. Esmon, Naomi L. Esmon, Deborah J. Stearns, Shinichiro Kurosawa
-
Patent number: 5179196Abstract: The present invention provides a process for the recovery of heterologous proteins from CTAP-III fusion proteins comprising expressing a fusion protein having a first amino acid sequence, a second amino acid sequence, and a selectable site which may be cleaved to provide first and second polypeptide fragments, respectively, wherein the first amino acid fragment is homologous to CTAP-III, and the first and second fragments have different pI values; cleaving the fusion protein to provide the first and second fragments; and separating the first and second fragments by ion exchange chromatography.Type: GrantFiled: May 4, 1989Date of Patent: January 12, 1993Assignee: SRI InternationalInventors: Paul H. Johnson, Ping Sze, Richard C. Winant, Jerome B. Lazar
-
Patent number: 4973667Abstract: Nuclear polyhedrosis viruses, for example, Autographa californica nuclear polyhedrosis virus (AcMNPV), useful in the control of lepidopterous larvae such as the larvae of the cabbage looper Trichoplusia ni, have been found to have enhanced infectivity when mixed with certain proteins obtained from the granulin fraction of Trichoplusia ni granulosis virus (TnGV) or Heliothis armigera granulosis virus (HaGV), and from the polyhedrin fraction of AcMNPV viruses. The proteins from the TnGV granulin fraction have molecular weights of about 101 and about 104 kd. The enhanced infectivity is correlated to biochemical and structural changes in the T.ni peritrophic membrane.Type: GrantFiled: October 25, 1989Date of Patent: November 27, 1990Assignee: Boyce Thompson Institute for Plant Research, Inc.Inventor: Robert R. Granados
-
Patent number: 5028694Abstract: A purified antigenic protein has been obtained which is capable of inducing in a chicken an immune response conferring protection against infection by Eimeria necatrix or Eimeria tenella. The protein has a molecular weight of about 26,000 and is composed of two polypeptides joined by a disulfide bond. The two polypeptide subunits have molecular weights of about 18,000 and about 8,000, respectively. The gene encoding the protein has been sequenced and the amino acid sequence of the protein deduced therefrom.The protein and antigenic polypeptides having an amino acid sequence included within the protein may be incorporated into a vaccine for conferring upon a chicken active immunity against infection by E. necatrix or E. tenella.Type: GrantFiled: December 3, 1985Date of Patent: July 2, 1991Assignee: Solvay & Cie, S.A.Inventors: Karel Z. Mewman, Jr., John L. Tedesco, Thomas C. Gore, Gary R. Petersen, Virginia M. Brothers, James G. Files, Leland S. Paul
-
Patent number: 5171842Abstract: A group of growth factors, designated heparin-binding brain mitogens (HBBMs), is disclosed. The HBBMs are isolated from brain tissue by a sequence of purification steps.Type: GrantFiled: November 1, 1991Date of Patent: December 15, 1992Assignee: American Cyanamid CompanyInventors: Peter Bohlen, Peter Gautschi-Sova
-
Patent number: 5354846Abstract: A non-toxic and non-cytolytic derivative of streptolysin O which retains at least one (preferably immunodominant) epitope is produced, and can be used especially in diagnostic tests for detecting of the presence of antibodies to Streptococcus pyogenes in a sample.Type: GrantFiled: June 8, 1993Date of Patent: October 11, 1994Inventor: Michael Kehoe
-
Patent number: 5141743Abstract: The present invention relates to a method for isolating and purifying transferrin and lactoferrin receptor proteins from bacterial pathogens by affinity chromatography and to vaccine antigens containing the purified receptor proteins.Type: GrantFiled: January 10, 1991Date of Patent: August 25, 1992Assignee: University Technologies International, Inc.Inventor: Anthony B. Schryvers
-
Patent number: 5021554Abstract: The particle size of amorphous protein material is reduced to uniform particulates without protein decomposition or loss of activity by passing the material through a fluid-energy mill.Type: GrantFiled: February 24, 1989Date of Patent: June 4, 1991Assignee: Eli Lilly and CompanyInventor: William W. Thompson
-
Patent number: 5504194Abstract: A lymphoid cell line cDNA that encodes an adhesion receptor for high endothelial venules (HEV).Type: GrantFiled: May 15, 1992Date of Patent: April 2, 1996Assignee: Fred Hutchinson Cancer Research CenterInventors: Thomas P. St. John, W. Michael Gallatin, Rejean L. Idzerda
-
Patent number: 5399668Abstract: A cDNA clone (HEV1) encoding hevein was isolated via polymerase chain reaction (PCR) using mixed oligonucleotides corresponding to two regions of hevein as primers and a Hevea brasiliensis latex cDNA library as a template. HEV1 is 1018 nucleotides long and includes an open reading frame of 204 amino acids. The deduced amino acid sequence contains a putative signal sequence of 17 amino acid residues followed by a 187 amino acid polypeptide. The amino-terminal region (43 amino acids) is identical to hevein and shows homology to several chitin-binding proteins and to the amino-termini of wound-induced genes in potato and poplar. The carboxyl-terminal portion of the polypeptide (144 amino acids) is 74-79% homologous to the carboxyl-terminal region of wound-inducible genes of potato. Wounding, as well as application of the plant hormones abscisic acid and ethylene, resulted in accumulation of hevein transcripts in leaves, stems and latex, but not in roots, as shown by using the cDNA as a probe.Type: GrantFiled: May 26, 1992Date of Patent: March 21, 1995Assignee: Board of Trustees operating Michigan State UniversityInventors: Natasha V. Raikhel, Willem F. Broekaert, Nam-Hai Chua, Anil Kush
-
Patent number: 5006642Abstract: A method of preparing von Willebrand Factor by disassociating it from a chaotropic agent in solution therewith and preferably treating the same under controlled temperature either in liquid or lyophilized form.Type: GrantFiled: June 13, 1988Date of Patent: April 9, 1991Assignee: Rhone-Poulenc Rorer Pharmaceuticals Inc.Inventors: Jack Newman, David L. Farb
-
Patent number: 5198423Abstract: This invention relates to a functional polypeptide containing the binding domain of human fibronectin and the heparin-binding domain of human fibronectin.Type: GrantFiled: May 22, 1990Date of Patent: March 30, 1993Assignee: Takara Shuzo Co., Ltd.Inventors: Yuki Taguchi, Yoh'ichi Ohdate, Yasutoshi Kawase, Shouichi Goto, Fusao Kimizuka, Ikunoshin Kato, Ikuo Saiki, Ichiro Azuma
-
Patent number: 4985544Abstract: Reactivation of cysteine-containing protein in a process, in which a reduced and denatured cysteine-containing protein such as salmon growth hormone I or eel growth hormone I can be efficiently reactivated.Type: GrantFiled: August 2, 1988Date of Patent: January 15, 1991Assignee: Kyowa Hakko Kogyo Co., Ltd.Inventors: Yoshiharu Yokoo, Seiji Sugimoto
-
Patent number: 4975529Abstract: A method of recovering biologically active somatotropins which are produced as insoluble refractile bodies in transformed microorganisms which comprises dissolving refractile bodies in a denaturant and 2-amino-2-methyl-1-propanol, homogenizing, and diluting to fold.Type: GrantFiled: August 18, 1989Date of Patent: December 4, 1990Assignee: Monsanto CompanyInventors: Ronald B. Frazier, Yasuo Konishi